Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
← catalyst calendarNCT07454837 · readout in 377 d
Sponsored by Mirum Pharmaceuticals, Inc. (industry) · MIRM — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
120estimated
Sites
35
Countries
Austria, Czechia, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-26 | actual | When the study began enrolling |
| Primary completion | 2027-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepatitis D
Interventions
- Drug: Brelovitug (BJT-778) — also filed as BJT-778
- Drug: Bulevirtide — also filed as BJT-778, Hepcludex
Primary outcome
what the primary-completion date above is the date OFProportion of participants with undetectable HDV RNA (<LLOQ Target not detected [TND])
measured Week 24
Permalink · MIRM's whole pipeline · Catalyst calendar · Every registered study · What changed